• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

TARIS Biomedical

edit

TARIS Biomedical a specialty pharmaceutical company with deep domain expertise in therapeutics and drug-delivery, is focused on local minimally-invasive drug-device convergence products. The TARIS core technology and development efforts are being applied to disease areas with high unmet medical need in which current therapies or systemic treatments have failed.

Milestones

edit

• 
  TARIS Biomedical added Ed Kania as Director.
  Posted 12/16/09 at 4:04pm
• 
  TARIS Biomedical added Michael A. Greeley as Director.
  Posted 12/16/09 at 4:04pm
• 
  TARIS Biomedical added Kevin Bitterman as Director.
  Posted 12/16/09 at 4:04pm
• 
  TARIS Biomedical added Robert Crane as CFO.
  Posted 12/16/09 at 4:04pm
• 
  TARIS Biomedical added Jessica Anderson as Executive Director, Program Management and Clinical Operations.
  Posted 12/16/09 at 4:04pm
• 
  TARIS Biomedical added Michael Cima as Founder.
  Posted 12/16/09 at 4:04pm
• 
  TARIS Biomedical added Christine Blunt as Founder, COO.
  Posted 12/16/09 at 4:04pm
• 
  TARIS Biomedical received $18.3M in Series B funding. (4/13/11)
  Posted 4/13/11 at 5:21am via businesswire.com
• 
  TARIS Biomedical received $15M in Series A funding. (6/25/09)
  Posted 6/26/09 at 9:06pm via bizjournals.com
• 
  TARIS Biomedical — has taken in $18.3 million in a Series B funding round (4/13/11)
  Posted 4/13/11 at 7:35am via masshightech.com

Videos

Screenshots

edit

Above: TARIS Biomedical
Uploaded: 6/27/09

Sources

1. Taris Biomedical raises $15 million (boston.bizjournals.com) [edit]
2. TARIS Closes $18.3 Million Series B Financing (eon.businesswire.com) [edit]
3. Taris Biomedical rounds up $18.3M in Series B financing (masshightech.com) [edit]